Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFL001 in Symptomatic Sacroiliac Joint Syndrome
NCT06415461Phase 1Active, not recruiting
- Sponsor
- University of Florida
- Start
- May 2024
- Primary completion
- Jan 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CFL001 in Sacroiliac Joint Syndrome (SIJS) (3 arms), sponsored by University of Florida. Primary endpoint: Number of participants with treatment-related adverse events at 180 days. Started May 2024; status: active, not recruiting.
02
Drugs
CFL001
03
Conditions
Sacroiliac Joint Syndrome (SIJS)
Beyond the preview
Go deeper on NCT06415461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415461.